Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors.
Pennel KAF, Hatthakarnkul P, Wood CS, Lian GY, Al-Badran SSF, Quinn JA, Legrini A, Inthagard J, Alexander PG, van Wyk H, Kurniawan A, Hashmi U, Gillespie MA, Mills M, Ammar A, Hay J, Andersen D, Nixon C, Rebus S, Chang DK, Kelly C, Harkin A, Graham J, Church D, Tomlinson I, Saunders M, Iveson T, Lannagan TRM, Jackstadt R, Maka N, Horgan PG, Roxburgh CSD, Sansom OJ, McMillan DC, Steele CW, Jamieson NB, Park JH, Roseweir AK, Edwards J. Pennel KAF, et al. Among authors: steele cw. J Exp Clin Cancer Res. 2024 Mar 1;43(1):64. doi: 10.1186/s13046-024-02958-4. J Exp Clin Cancer Res. 2024. PMID: 38424636 Free PMC article.
Timing is everything: Brca2 and p53 mutations in pancreatic cancer.
Morton JP, Steele CW, Sansom OJ. Morton JP, et al. Among authors: steele cw. Gastroenterology. 2011 Apr;140(4):1143-6. doi: 10.1053/j.gastro.2011.02.026. Epub 2011 Feb 23. Gastroenterology. 2011. PMID: 21352873 No abstract available.
Exploiting inflammation for therapeutic gain in pancreatic cancer.
Steele CW, Jamieson NB, Evans TR, McKay CJ, Sansom OJ, Morton JP, Carter CR. Steele CW, et al. Br J Cancer. 2013 Mar 19;108(5):997-1003. doi: 10.1038/bjc.2013.24. Epub 2013 Feb 5. Br J Cancer. 2013. PMID: 23385734 Free PMC article. Review.
CXCR2 inhibition suppresses acute and chronic pancreatic inflammation.
Steele CW, Karim SA, Foth M, Rishi L, Leach JD, Porter RJ, Nixon C, Jeffry Evans TR, Carter CR, Nibbs RJ, Sansom OJ, Morton JP. Steele CW, et al. J Pathol. 2015 Sep;237(1):85-97. doi: 10.1002/path.4555. Epub 2015 Jun 4. J Pathol. 2015. PMID: 25950520 Free PMC article.
Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy.
Miller BW, Morton JP, Pinese M, Saturno G, Jamieson NB, McGhee E, Timpson P, Leach J, McGarry L, Shanks E, Bailey P, Chang D, Oien K, Karim S, Au A, Steele C, Carter CR, McKay C, Anderson K, Evans TR, Marais R, Springer C, Biankin A, Erler JT, Sansom OJ. Miller BW, et al. EMBO Mol Med. 2015 Aug;7(8):1063-76. doi: 10.15252/emmm.201404827. EMBO Mol Med. 2015. PMID: 26077591 Free PMC article.
CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma.
Steele CW, Karim SA, Leach JDG, Bailey P, Upstill-Goddard R, Rishi L, Foth M, Bryson S, McDaid K, Wilson Z, Eberlein C, Candido JB, Clarke M, Nixon C, Connelly J, Jamieson N, Carter CR, Balkwill F, Chang DK, Evans TRJ, Strathdee D, Biankin AV, Nibbs RJB, Barry ST, Sansom OJ, Morton JP. Steele CW, et al. Cancer Cell. 2016 Jun 13;29(6):832-845. doi: 10.1016/j.ccell.2016.04.014. Epub 2016 Jun 2. Cancer Cell. 2016. PMID: 27265504 Free PMC article.
56 results